Pharmaceutical Technology

FEBRUARY 20, 2023

Other lines of research look at the genetic overlap between FTD and amyotrophic lateral sclerosis (ALS), which could be used in the development of treatments for both conditions. This is also one of the major challenges that slow the development of effective treatments for FTD, he adds. This protein promotes lysosomal function.

Development 246

Development Gene Therapy Protein Gene 246

Pharmaceutical Technology

SEPTEMBER 25, 2024

Generate:Biomedicines and Novartis have partnered for the discovery and development of protein therapeutics in multiple disease areas.

Protein 130

Protein Development 130

Pharmaceutical Technology

DECEMBER 23, 2022

Eli Lilly and Company has expanded a licencing and partnership agreement with ProQR Therapeutics to discover, develop and market new genetic medicines. The post Lilly and ProQR to expand genetic medicine development agreement appeared first on Pharmaceutical Technology.

Genetics 328

Genetics Medicine Development Gene Therapy 328

Bio Pharma Dive

DECEMBER 6, 2022

Entact Bio aims to develop medicines that can enhance helpful proteins, rather than block harmful ones, a twist on the usual drugmaking playbook.

Protein 207

Protein Medicine Development 207

Pharmaceutical Technology

MAY 17, 2023

Chinook Therapeutics and Ionis Pharmaceuticals have entered a partnership to develop an antisense oligonucleotide (ASO) therapy to treat a rare, severe chronic kidney disease. The collaboration aims to discover, develop and commercialise an ASO therapy.

Development 246

Development Protein RNA Genetics 246

Pharmaceutical Technology

FEBRUARY 16, 2023

Aqilion and Merck have entered an exclusive licence and strategic research partnership for the discovery, development and commercialisation of the transforming growth factor-β-activated kinase 1 (TAK1) protein-small molecule inhibitors. Aqilion will handle the design and synthesis of the new small molecule TAK1 inhibitors.

Protein 147

Protein Development Sales Business Development 147

Pharmaceutical Technology

AUGUST 29, 2024

GlobalData’s report assesses the drugs in the E3 Ubiquitin Protein Ligase CBL B pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

Protein 130

Protein Development Drugs 130

XTalks

MARCH 18, 2025

In today’s food and beverage industry, protein enrichment has become a pivotal trend, driven by consumers’ growing awareness of health and nutrition. High-protein products are in demand across various categories, from bakery and dairy (alternatives) to sports nutrition and savoury foods.

Protein 52

Protein Manufacturing Production Branding 52

Pharmaceutical Technology

AUGUST 29, 2024

The Putative Fidgetin Like Protein 2 pipeline drugs market research report outlays comprehensive information on the Putative Fidgetin Like Protein…

Protein 130

Protein Drugs Development Marketing 130

Pharmaceutical Technology

NOVEMBER 29, 2023

GlobalData’s report assesses the drugs in the Bromodomain Containing Protein 4 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

Containment 130

Containment Protein Development Drugs 130

Pharmaceutical Technology

MAY 9, 2023

Ginkgo Bioworks and Boehringer Ingelheim have collaborated to develop breakthrough therapies for hard-to-treat diseases. The companies will use the natural product discovery capabilities of Ginkgo Bioworks to expedite the discovery and development of new therapeutic molecules to address diseases with high unmet patient needs.

Development 261

Development Protein Sales Production 261

Bio Pharma Dive

OCTOBER 28, 2020

The two Swiss firms will develop protein drugs that are meant to have similar effects as coronavirus antibodies, but would be easier to mass produce.

Development 206

Development Drugs Protein Antibody 206

Bio Pharma Dive

DECEMBER 16, 2022

The pharma will pay Sosei $37 million upfront to discover new candidates for diabetes and metabolic diseases that target G protein-coupled receptors.

Protein 154

Protein Development Drugs 154

Pharmaceutical Technology

JUNE 6, 2023

Oragenics has secured funding from the Canadian bioresearch consortium CQDM to develop a variant-agnostic protein antigen for use in its Covid-19 intranasal vaccine. In March 2023, Oragenics and Inspirevax entered an exclusive global licence deal to develop the former’s lead intranasal Covid-19 vaccine candidate, NT-CoV2-1.

Vaccination 231

Vaccination Vaccine Development Manufacturing 231

Pharmaceutical Technology

DECEMBER 7, 2022

Alongside the discourse on what the positive study results could mean for patients, researchers are prioritising the development of more biomarkers to identify potential responders and improve patient outcomes. Developing treatment biomarkers and diagnostic biomarkers may help achieve these goals. Amyloid-targeting therapies.

Development 264

Development Drugs Clinical Trials Clinical Trials 264

Pharmaceutical Technology

APRIL 6, 2023

Biotheryx and Incyte have signed an agreement for identifying and developing targeted protein degraders for historically undruggable oncology targets. Further development and commercialisation of any molecular glue degraders will be handled by Incyte alone. These degraders will be identified by the PRODEGY platform.

Protein 130

Protein Development Sales Production 130

Pharmaceutical Technology

AUGUST 30, 2024

GlobalData’s report assesses the drugs in the Gap Junction Beta 2 Protein pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

Protein 100

Protein Development Drugs 100

Pharma Times

APRIL 26, 2024

The paper identifies the roles of LARP4A and LARP4B in sarcoma and carcinoma cancers

RNA 149

RNA Protein Development 149

Bio Pharma Dive

MARCH 30, 2021

Two drugs developed by Wave Life Sciences didn't appear to have an effect on disease-causing proteins, another setback for Huntington's research after disappointing results last week from Roche and Ionis.

Life Science 310

Life Science Drugs Protein Trials 310

Pharmaceutical Technology

AUGUST 30, 2024

GlobalData’s report assesses the drugs in the Dynamin Like 120 kDa Protein Mitochondrial pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

Protein 100

Protein Development Drugs 100

Pharma Times

JULY 26, 2024

Researchers predicted the onset of 67 diseases, out-performing current standard models

Protein 150

Protein Development Research Biobanking 150

Pharmaceutical Technology

DECEMBER 7, 2022

Alongside the discourse on what the positive study results could mean for patients, researchers are prioritising the development of more biomarkers to identify potential responders and improve patient outcomes. Developing treatment biomarkers and diagnostic biomarkers may help achieve these goals. Amyloid-targeting therapies.

Development 246

Development Drugs Clinical Trials Clinical Trials 246

Pharma Times

APRIL 29, 2024

The new process makes generating active pharmaceutical ingredients quicker and easier

Protein 170

Protein Development Research Drugs 170

Pharmaceutical Technology

DECEMBER 7, 2023

GlobalData’s report assesses the drugs in the Cholesteryl Ester Transfer Protein pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

Protein 100

Protein Development Drugs 100

Pharmaceutical Technology

NOVEMBER 29, 2023

GlobalData’s report assesses the drugs in the Tyrosine Protein Kinase JAK1 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

Protein 100

Protein Development Drugs 100

Pharmaceutical Technology

NOVEMBER 29, 2023

GlobalData’s report assesses the drugs in the Myc Proto Oncogene Protein pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

Protein 100

Protein Development Drugs 100

Pharmaceutical Technology

APRIL 26, 2023

This investment will be used to further the development of the Singapore-based pharmaceutical company’s solid tumour-focused monoclonal antibodies. The funding and a prize-win from Amgen will support the company’s drug development plans as Singapore continues developing its pharmaceutical market.

Development 256

Development Drugs Marketing Protein 256

Pharmaceutical Technology

DECEMBER 7, 2023

GlobalData’s report assesses the drugs in the Protein Kinase C Theta Type pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

Protein 100

Protein Development Drugs 100

Bio Pharma Dive

MARCH 11, 2024

Sosei Heptares could receive more than 700 million euros in a deal to develop medicines aimed at the protein GPR52, an emerging drug target in multiple neurological diseases.

Drugs 281

Drugs Protein Medicine Development 281

Pharmaceutical Technology

APRIL 13, 2023

Dyadic International has announced expansion of a licence agreement for its C1-cell protein expression platform with South African consortium Rubic One Health. The expanded licence will include the development of vaccines and therapeutic proteins beyond Covid-19 for human and animal health markets in Africa.

Production 279

Production Vaccine Vaccination Protein 279

Bio Pharma Dive

FEBRUARY 23, 2023

Sanofi and its development partner, Sobi, claim the drug’s once-a-week dosing, and its effect on blood-clotting protein levels, will help it compete in the crowded market for hemophilia A treatments.

FDA Approval 281

FDA Approval Drugs Protein Marketing 281

Bio Pharma Dive

SEPTEMBER 20, 2023

Targeted protein degradation has emerged as one of the more competitive areas of pharmaceutical research in recent years as scientists develop new ways to reach difficult-to-drug targets.

Drugs 271

Drugs Protein Scientist Development 271

Pharmaceutical Technology

OCTOBER 10, 2023

The companies will develop multiple monoclonal antibodies against membrane proteins, such as GPCRs and SLC transporters.

Antibody 147

Antibody Development Protein 147

Pharmaceutical Technology

OCTOBER 17, 2023

SpliceBio will license Spark Therapeutics’ propriety protein splicing platform to develop a gene therapy for renal disease.

Gene Therapy 246

Gene Therapy Gene Licensing Licensing 246

Pharmaceutical Technology

MARCH 26, 2024

Discover Innovent Biologics' groundbreaking patent for novel proteins with heterodimeric antibody Fc, revolutionizing antibody engineering and drug development.

Protein 130

Protein Engineer Antibody Development 130

Medical Xpress

NOVEMBER 22, 2024

LMU researchers have discovered how the interplay between a key protein and an endolysosomal ion channel promotes tumor development in skin cancer.

Development 133

Development Scientist Protein Research 133

Pharmaceutical Technology

MARCH 21, 2023

Gilead Sciences has exercised its option to exclusively license the investigational targeted protein degrader development candidate, NX‑0479, from clinical-stage biopharmaceutical company Nurix Therapeutics. GS-6791 is the first development candidate from the previous collaboration between Gilead Sciences and Nurix in 2019.

Protein 130

Protein Licensing Licensing Sales 130